AstraZeneca shares drop as lung cancer trial update lags expectations

The drug, datopotamab deruxtecan, which is being jointly developed with Japan's Daiichi Sankyo, was shown to prolong progression-free survival compared with standard chemotherapy in patients whose non-small cell lung cancer had returned after one or two prior treatment attempts.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/9kTNdmH
via